Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDGE-Gastric: Phase 2 Combination Therapies for Advanced Upper Gastrointestinal Tract Malignancies
2024-511917-40-00Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2 trial of zimberelimab, domvanalimab and quemliclustat in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more, sponsored by Arcus Biosciences. Primary endpoints: Incidence and severity of adverse events and Objective response rate by RECIST v1.1. Started Sep 2022; status: completed.
02
Drugs
zimberelimabdomvanalimabquemliclustat
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)Upper gastrointestinal tract cancer
Beyond the preview
Go deeper on 2024-511917-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511917-40-00.